Universite de Montreal - Canada

Universite de Montreal - Canada

Universite de Montreal - Canada

Overview
Date Founded

1878

Headquarters

succursale Centre-ville,Montréal, QC

Employees (Worldwide)

501 - 1,000

Industries

IT Consulting & Services
Schools & Student Services

Company Description

The Université de Montréal is a public research university in Montreal, Quebec, Canada. The francophone institution comprises thirteen faculties, more than sixty departments and two affiliated schools: the École Polytechnique (School of Engineering) and HEC Montréal (School of Business). It offers more than 650 undergraduate programmes and graduate programmes.

Executives & Employees

Associate Governor

Provost & Vice-Rector-Academic Affairs

Acting Dean of the Faculty of Graduate & Postdoctoral Studies

Rector

Director of Ecole de Sante Publique

Director-Management & Investments, Pension Plan

Associate Vice-Rector, Student Life

Full Professor

Full Professor

Board of Directors

Former Senior Vice President, Corporate & Legal Services & Secretary at Intact Financial Corp.

Vice Chairman at Power Corp. of Canada

Former President-Quebec at Deloitte & Touche, Inc.

Former Senior Vice President, Human Resources, Corporate Affairs & Strategic Initiatives at National Bank of Canada

Vice President, Site Manufacturing at Acrimax

Chief Executive Officer at Gladius Pharmaceuticals, Inc.

Fund Advisor at Ontario Teachers' Pension Plan Board

Former Director, President & Chief Executive Officer at RONA, Inc.

Distinguished Alumni
Pierre-Yves Leduc is now Director & Chief Executive at Velan, Inc.
Jacques Foisy is now Chairman of the Board & Managing Partner at Novacap Management, Inc.
Salim G. Sfeir is now Chief Executive Officer at Bank of Beirut sal
Paths to Universite de Montreal - Canada
Potential Connections via
Relationship Science
You
Universite de Montreal - Canada
Clients

Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded on June 12, 2015 and is headquartered in Amsterdam, the Netherlands.

Key Stats and Financials As of 2012
Market Capitalization
Total Enterprise Value
Earnings Per Share
Revenue
$974M
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$200K
12/31/2017
$50K
12/31/2017
$200K
12/31/2016
Investments
Details Hidden

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Universite de Montreal - Canada. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Universite de Montreal - Canada's profile does not indicate a business or promotional relationship of any kind between RelSci and Universite de Montreal - Canada.